The addition of AcroMetrix will accelerate the expansion of our focused commercial channel for reaching molecular diagnostics customers, both with the current product portfolio and with assays in development, said Mark Stevenson, Life Technologies ™ President and Chief Operating Officer. Our objective is to become the technology partner of choice to organizations worldwide that are building out their molecular diagnostic capabilities.

We ™re pleased to add our superior line of products to Life Technologies ™ comprehensive suite of offerings in the molecular diagnostics market, said Michael J. Eck, President and Chief Executive Officer of AcroMetrix. Our customers will now benefit from even greater investment in new molecular products designed to meet the needs of clinical laboratories.

The transaction is subject to customary closing conditions. Life Technologies does not expect this transaction to have a material effect on its financials in fiscal year 2010.

Source: Life Technologies Corporation